BACKGROUND: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. METHODS: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. RESULTS: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. CONCLUSIONS: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
BACKGROUND: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. METHODS: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. RESULTS: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. CONCLUSIONS: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
Authors: Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier Journal: N Engl J Med Date: 2016-02-22 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Linda-Gail Bekker; Surita Roux; Elaine Sebastien; Ntando Yola; K Rivet Amico; James P Hughes; Mark A Marzinke; Craig W Hendrix; Peter L Anderson; Vanessa Elharrar; Michael Stirratt; James F Rooney; Estelle Piwowar-Manning; Susan H Eshleman; Laura McKinstry; Maoji Li; Bonnie J Dye; Robert M Grant Journal: Lancet HIV Date: 2017-10-03 Impact factor: 12.767
Authors: Ariane van der Straten; Elizabeth T Montgomery; Petina Musara; Juliane Etima; Sarita Naidoo; Nicole Laborde; Miriam Hartmann; Lisa Levy; Thola Bennie; Helen Cheng; Jeanna Piper; Cynthia I Grossman; Jeanne Marrazzo; Barbara Mensch Journal: AIDS Date: 2015-10-23 Impact factor: 4.177
Authors: Elizabeth T Montgomery; Ariane van der Straten; Agnes Chidanyika; Tsungai Chipato; Shabbar Jaffar; Nancy Padian Journal: AIDS Behav Date: 2011-07
Authors: Michele Lanham; Rose Wilcher; Elizabeth T Montgomery; Robert Pool; Sidney Schuler; Rachel Lenzi; Barbara Friedland Journal: J Int AIDS Soc Date: 2014-09-08 Impact factor: 5.396
Authors: J Hanass-Hancock; S Hoffman; S Bergam; A D Harrison; N Benghu; S Khumalo; N Tesfay; T Exner; L Miller; C Dolezal Journal: AIDS Behav Date: 2022-02-26
Authors: Elizabeth T Montgomery; Erica N Browne; Millicent Atujuna; Marco Boeri; Carol Mansfield; Siyaxolisa Sindelo; Miriam Hartmann; Sheily Ndwayana; Linda-Gail Bekker; Alexandra M Minnis Journal: J Acquir Immune Defic Syndr Date: 2021-07-01 Impact factor: 3.771
Authors: Luh Putu Lila Wulandari; Shi Yi He; Christopher K Fairley; Benjamin R Bavinton; Heather Marie-Schmidt; Virginia Wiseman; Rebecca Guy; Weiming Tang; Lei Zhang; Jason J Ong Journal: EClinicalMedicine Date: 2022-07-09
Authors: Alexandra M Minnis; Millicent Atujuna; Erica N Browne; Sheily Ndwayana; Miriam Hartmann; Siyaxolisa Sindelo; Nangamso Ngcwayi; Marco Boeri; Carol Mansfield; Linda-Gail Bekker; Elizabeth T Montgomery Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396
Authors: S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge Journal: AIDS Res Ther Date: 2020-02-04 Impact factor: 2.250
Authors: Emily A Krogstad; Millicent Atujuna; Elizabeth T Montgomery; Alexandra M Minnis; Chelsea Morroni; Linda-Gail Bekker Journal: Cult Health Sex Date: 2020-03-27